


NexoBrid[®]

Disruptive Bioactive Therapy
for Burn Care



Eschar Removal

Critical First Step in Burn Care



Prevents infection
and sepsis

Stops deterioration
and scarring

Tissue visible for
medical evaluation

Traumatic SOC¹

Surgical, Non-Selective



Loss of
healthy tissue
and blood

Challenging
in delicate
areas

Requires
surgical team,
operating room

NexoBrid: Rapid, Effective, and Selective



- Sterile mixture of proteolytic enzymes
- Globally approved for eschar removal in adult and pediatric burn patients in 40+ countries
- 16,000+ patients treated to date
- Topical application at patient's bedside
- Minimizes need for surgery and significantly reduces blood loss

- Improves patient outcomes (scar quality and function)
- Removes eschar within 4 hours
- Enables visual medical assessment
- Extensive government funding: \$138M received from BARDA and DoW
- Commercially available in U.S., EU, JP

¹standard of care